BioSpace News Archive

ConcertAI’s TeraRecon has announced its Eureka Clinical AI platform is now available to European healthcare providers.

Protalix BioTherapeutics, Inc. today reported financial results for the fiscal year ended December 31, 2022 and provided a business update on recent corporate and regulatory developments.

Passage Bio, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights.

Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference.

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T.

Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients who fall within the scope of the European marketing authorization in Sweden.

Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research supporting the company’s cardiovascular franchise at the American College of Cardiology (ACC) Annual Scientific Session & Expo together with the World Congress of Cardiology (WCC), taking place in-person and virtually March 4-6, 2023.